FDA Yanks 15 Teva Generic Approvals for Dormant Drugs
Published Date: 5/7/2026
Notice
Summary
The FDA is officially pulling the plug on 15 generic drug approvals from Teva Pharmaceuticals and its related companies because these drugs aren’t being sold anymore. This change kicks in on June 8, 2026, and it won’t cost anyone money or cause shortages since the drugs are off the market. If Teva wants, they can ask to sell these drugs again later without any trouble.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
FDA withdraws 15 generic approvals
The FDA is withdrawing approval of 15 abbreviated new drug applications (ANDAs) from multiple applicants, including Teva Pharmaceuticals USA and related companies, effective June 8, 2026. The listed applicants requested withdrawal and waived their opportunity for a hearing. The withdrawal is without prejudice to refiling, so applicants may submit new applications later.
Existing stock can still be dispensed
If any of the listed drug products are in inventory on June 8, 2026, they may continue to be dispensed until inventories are depleted, the products reach their expiration dates, or they otherwise become violative. After those conditions occur, the products may not be introduced into interstate commerce without an approved application.
FDA says no cost or shortage expected
The FDA states the withdrawals apply to drug products that are no longer marketed and that the change takes effect on June 8, 2026. Because these products are off the market, the action is described as not causing costs to consumers or drug shortages.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
Previous / Next Documents
Previous: 2026-09011 — Determination That MICARDIS (Telmisartan), Tablets, 20 Milligrams and 80 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that MICARDIS tablets (20 mg and 80 mg) were not taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved, helping patients access affordable options without delays. If you use or make these meds, no sudden changes or extra costs are coming your way anytime soon!
Next: 2026-09013 — Final Flood Hazard Determinations
FEMA has finalized updates to flood risk maps for certain communities, changing flood zones and water levels that affect flood insurance rules. Homeowners, renters, and local governments in these areas need to check the new maps by June 23, 2026, to stay protected and insured. These changes could impact insurance costs and building rules, so it’s smart to stay informed and prepared!